Author

T. P. Heffernan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 6

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:cancer & tumor microenvironment· 4 Organism:mouse· 4 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:clustering· 1 Approach:deep learning· 1 Research Focus:differential expression· 1

Frequent Co-Authors

C. A. Bristow· 4 shared A. Maitra· 3 shared A. Viale· 3 shared G. F. Draetta· 3 shared H. Ying· 3 shared W. Yao· 3 shared A. Carugo· 2 shared C. Zhu· 2 shared

Activity by Year

2019-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

C. A. Bristow

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

KRAS inhibition activates an actionable CD24 do-not-eat-me signal in pancreatic cancer

Y. Wei, M. Liu, E.-Y. Yen, J. Yao, Z. Xun, P. T. Nguyen, X. Wang, Z. Yang, A. Yousef, D. Pan, Y. Jin, C.-F. Li, M. S. Theardy, J. Park, Y. Cai, , H. Ying

This study identifies CD24 as an actionable signal activated by KRASG12C inhibition in pancreatic cancer, enhancing macrophage phagocytosis and sensitizing tumors to therapy.

bioRxiv · Sep 21, 2023Cancer Biology

Oncogenic KrasG12D specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8+ T cells dependent manner

K. K. Mahadevan, K. McAndrews, V. LeBleu, S. Yang, H. Lyu, B. Li, A. M. Sockwell, M. L. Kirtley, S. J. Morse, B. M. Moreno Diaz, M. P. Kim, N. Feng, A. M. Lopez, P. A. Guerrero, H. Sugimoto, , R. Kalluri

This study shows that MRTX1133, a KrasG12D inhibitor, reduces early pancreatic lesions and, when combined with immunotherapy, regresses advanced PDAC by enhancing CD8+ T cell activity.

bioRxiv · Feb 15, 2023 · PreprintCancer Biology

Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance

V. Thatikonda, H. Lu, S. Jurado, K. Kostyrko, C. A. Bristow, K. Bosch, N. Feng, S. Gao, D. Gerlach, M. Gerlach, S. Lieb, A. Jeschko, A. A. Machado, E. D. Marszalek, M. Mahendra, , M. H. Hofmann

This study shows that combining KRASG12C and SOS1 inhibitors improves anti-tumor response and delays resistance in KRASG12C-driven cancers.

bioRxiv · Jan 23, 2023Cancer Biology

9p21 Loss Defines the Evolutionary Patterns of Aggressive Renal Cell Carcinomas

F. Carbone, J. K. Huang, L. Perelli, E. Del Poggetto, T. Gutschner, H. Tomihara, M. Soeung, T. N. A. Lam, R. Xia, C. Zhu, X. Song, J. Zhang, K. Sircar, G. G. Malouf, A. Sgambato, , G. Genovese

This study establishes a mouse model of renal cell carcinoma showing that 9p21 loss drives aggressive tumor evolution with chromosomal instability and metastasis.

bioRxiv · Nov 3, 2020 · PreprintCancer Biology

Diversity Across the Pancreatic Ductal Adenocarcinoma Disease Spectrum Revealed by Network-Anchored Functional Genomics

J. L. Rose, S. Srinivasan, W. Yao, S. Seth, M. Peoples, A. Machado, C.-Y. Li, I. L. Ho, J. J. Lee, P. A. Guerrero, E. Kim, M. Syed, J. R. Daniele, A. Deem, M. Kim, , G. F. Draetta

This study introduces CoDEX, a framework that links gene-cluster patterns with genetic vulnerabilities in PDAC, revealing subtype-specific dependencies and their impact on tumor phenotypes.

bioRxiv · Sep 17, 2020 · PreprintCancer Biology

YAP1 Oncogene is a Context-specific Driver for Pancreatic Ductal Adenocarcinoma

B. Tu, J. Yao, S. Ferri-Borgogno, J. Zhao, S. Chen, Q. Wang, L. Yan, X. Zhou, C. Zhu, S. Bang, Q. Chang, C. A. Bristow, Y. Kang, H. Zheng, H. Wang, , H. Ying

This study identifies YAP1 as a context-specific driver for the squamous subtype of pancreatic ductal adenocarcinoma and shows WNT5A promotes tumor progression through YAP1 activation.

bioRxiv · Aug 17, 2019Cancer Biology